Abcam & Research-Use Antibodies: Customer Perspective II
Former VP, Biology at CyVek
inpractise.com/articles/abcam-and-research-use-antibodies-
Why is this interview interesting?
- Buying research use antibodies from Abcam vs R&D Systems
- Perspectives on the opportunity for Abcam in proteomics
- Comparison of RUA vendor pricing strategies
- Demand outlook for research use antibodies
Former VP, Biology
Former VP, Biology at CyVek
This executive has a background in nucleic acid amplification, next-generation DNA sequencing, microfluidics, genetics, molecular biology and product development, with experience in innovative technology development from the initial start-up to product launch stage. He is currently the SVP R&D at IsoPlexis, and previously held senior roles 4Catalyzer and Quantum-Si and Qiagen among others. At Qiagen he was Head of the global Next Generation Sequencing (NGS) development team, responsible for management of the technology development driving QIAGEN’s NGS GeneReader system.
Interview Transcript
This is a snippet of the transcript, sign up to read more.
Related Content
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2023 IP 1 Ltd. All rights reserved.